May 06, 2021
published at 7:30 AMglobenewswire
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
GlobeNewswire
May 06, 2021
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid.
(0)
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid.
6 may 2021
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid.
Search jobs 30-Apr-2021 Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
SYDNEY, AUSTRALIA – 29 April 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June.
E-Mail
The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in
NPJ Precision Oncology (10.1038/s41698-021-00171-6)
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic approach used for most targeted therapies provides limited treatment options, with a binary yes/no expected response to a drug and no recommendation for which treatment, among a range of possible options, is likely to be the best option